At #SOHO2025, Asfand Yar Cheema of @clevelandclinic.bsky.social stopped by to share insights into the clinical outcomes of patients with #PolycythemiaVera or MDS treated with GLP-1 agonists.

Click here to watch the interview:

👉 buff.ly/KcqIbrj 👈

#MDSsm #MPNsm #HemOnc #BloodSky #HemeSky #MedSky

As today is World MDS Awareness Day, why not check out our MDS channel?🩸

You'll find the latest updates in MDS straight from leading experts in the form of video interviews, roundtable discussions, feature articles, podcasts, & more!🎥🎧

Click here to explore: 👉 buff.ly/aWAEu6k

#MDSWAD2025 #MDSsm

Today is MDS World Awareness Day!🩸🌎

In an interview from earlier this year, Valeria Santini discussed the use of immunosuppressive therapy in MDS, highlighting available agents & areas for further research:

👉 buff.ly/OsY3ebW 👈

#MDSWAD2025 #HemOnc #MDSsm #BloodSky #HemeSky #MedSky

At #SOHO2025, we caught up with Valeria Santini, who provided an overview of recent advances in the treatment of lower-risk MDS, with a focus on therapies for anemia.🩸

Click here to watch the interview:

👉 buff.ly/OBaMhs6 👈

#MDSsm #HemOnc #BloodSky #HemeSky #MedSky

🎥 Sanam Loghavi and Guillermo Montalban-Bravo of @mdanderson.bsky.social sat down at #iwAL25 to share insights into the diagnosis and classification of CMML, commenting on how the current approach to this could be refined:

👉 buff.ly/5ZwQxnP 👈

#Leusm #HemOnc #RareDisease #MDSsm #BloodSky #HemeSky

In an interview from #SOHO2025, Matteo Della Porta shares insights into the significance of anemia in MDS & MPNs, highlighting the need to develop effective therapies for this clinical feature.

Click to watch:

👉 buff.ly/rXyC3pf 👈

#MDSsm #MPNsm #HemOnc #BloodSky #HemeSky #MedSky

In an interesting interview from #SOHO2025, David Swoboda discusses the development of a novel AI-driven virtual tumor board designed to improve diagnosis, prognosis, and treatment recommendations in MDS.

Watch here:

🎥 buff.ly/wrh0OvA

#MDSsm #HemOnc #AI #BloodSky #HemeSky #MedSky

It was a pleasure to catch up with David Sallman of @moffittnews.bsky.social at #SOHO2025 to hear about promising novel concepts being explored for the treatment of TP53-mutated.🩸

Want to learn more?

Click here to watch:
👉 buff.ly/2rbgMwQ 👈

#MDSsm #HemOnc #BloodSky @societyofhemonc.bsky.social

Did you miss out on #SOHO2025?

Don’t worry! You can catch up with all the latest advancements from the meeting by checking out our exclusive interviews with leading #HemOnc experts below:

👉 buff.ly/tgyYWhf

#ImmunoOnc #LymSM #MPNsm #MDSsm #LeuSM #BloodSky #MedSky @societyofhemonc.bsky.social

In an insightful interview, Idoroenyi Amanam of @cityofhope.bsky.social discusses real-world data on the outcomes of US patients with lower-risk MDS treated with luspatercept in the first-line setting.

Click here to watch:
👉 buff.ly/EiFxYRa 👈

#MDSsm #HemOnc #EHA2025 #BloodSky #HemeSky #MedSky

🎥 Shaun Fleming presents early safety and efficacy findings of LAVA-1266, a CD123-targeting Vγ9Vδ2-T cell engager, in patients with R/R AML or HR-MDS:

👉 buff.ly/GIoMPtN 👈

#MDSsm #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #EHA2025 #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

How are clinical trials evolving in MDS?💭

At #iwMDS25, leading experts Maximilian Stahl, Rami Komrokji, & Coleman Lindsley discussed redefining response criteria & improving study design to advance care.🩸

Don’t miss this insightful session:

🎥 👉 buff.ly/cj2cXpS

#MDSsm #HemOnc #CTSM #BloodSky

At #iwMDS25, leading experts @abrunner.bsky.social, @mikkaelsekeres.bsky.social, & Lionel Ades shared insights into recent advances in the treatment & management of LR-MDS.🩸

Check out the roundtable discussion here:

👉 buff.ly/SkpE0p4 👈

#MDSsm #HemOnc #BloodSky #HemeSky #MedSky

Olutasidenib is Highly Effective in Certain Patients with Myelodysplastic Syndrome The novel targeted drug olutasidenib has been shown to be effacacious in select patients with MDS.

Olutasidenib is Highly Effective in Certain Patients with Myelodysplastic Syndrome
#MDS #MDSSM #hematology
www.onclive.com/view/olutasi...

Want to hear about updates & advances in MDS classification & risk stratification?🩸

Watch our fantastic roundtable discussion from #iwMDS25 with experts Uma Borate, Luca Lanino, Robert Hasserjian, & @zoeyxie.bsky.social:

🎥 buff.ly/Yr2mKl8

#MDSsm #HemOnc #BloodSky #HemeSky #MedSky

Want to hear about updates & advances in MDS classification & risk stratification?🩸

Watch our fantastic roundtable discussion from #iwMDS25 with experts Uma Borate, Luca Lanino, Robert Hasserjian, & Zhuoer Xie:

🎥 buff.ly/UtUKM0w

#MDSsm #HemOnc #BloodSky #HemeSky #MedSky

Evolution of MDS Management Hinges on Standardized Disease Classification, Molecularly Informed Risk Stratification Hetty E. Carraway, MD, MBA, highlights the evolving molecular classification of MDS and novel agents in the therapeutic arsenal.

Evolution of MDS Management Hinges on Standardized Disease Classification, Molecularly Informed Risk Stratification
@carrawayhetty.bsky.social @clevelandclinic.bsky.social #MDS #mdssm
www.onclive.com/view/evoluti...

Oral Decitabine-Cedazuridine Is a Game Changer for MDS and CMML Treatment The oral formulation of decitabine-cedazuridine helps empower patients with MDS or CMML to maintain their quality of life from the comfort of their home.

Oral Decitabine-Cedazuridine Is a Game Changer for MDS and CMML Treatment
#mdssm #leusm
www.onclive.com/view/oral-de...

Want a comprehensive overview of the current treatment options for patients with lower-risk MDS and anemia?🩸

Then don't forget to check out our fantastic interview with Valeria Santini from #EHA2025!😄

Watch here:
🎥 buff.ly/D4eOZ2R

#MDSsm #HemOnc #BloodSky #HemeSky #MedSky

Opinion: Top Studies From EHA 2025 Ashwin Kishtagari, MD, of Vanderbilt University Medical Center in Nashville, summarizes 7 studies presented at the EHA 2025 Congress.

The recent EHA 2025 Congress showcased novel combinations for MDS and AML as well as a novel formulation of a drug for B-ALL: an opinion piece by @ashkishtaagri.bsky.social of @vanderbilt.edu shorturl.at/RkY2M #EHA2025 #leusm #mdssm

Full text access to our review about iron chelation therapy in #MDSsm and allogeneic #HCT in Blood Reviews.

authors.elsevier.com/c/1lLPl,67Ou...

🚨 Hear results from the BEXMAB study investigating the efficacy of bexmarilimab plus azacitidine in MDS!

Watch our interview from #EHA2025 with Dr Mika Kontro here:

👉 buff.ly/HPeUP6m 👈

#MDSsm #CTSM #TrialUpdate #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

At #EHA2025 last week, Amer Zeidan gave an update on immune checkpoint inhibition in MDS & AML, highlighting the promise of novel agents sabatolimab and bexmarilimab.🩸

Watch the interview here:
👉 buff.ly/mVSYBHP

#AMLsm #MDSsm #Leusm #TrialUpdate #ImmunoOnc #BloodSky #HemeSky #CTSM

VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MDS Venetoclax plus azacitidine did not yield an OS benefit vs placebo plus azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes.

VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MDS
#MDS #mdssm
www.onclive.com/view/verona-...

AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome...

news.abbvie.com/2025-06-16-A... Wow — top line VERONA results are negative — no advantage to AZA + VEN compared to AZA alone for higher-risk #MDSsm. AZA or DAC alone remain the standard for HR-MDS. So disappointing😢 🎗️🩸

Dr Amer Zeidan interviewing with VJHemOnc at EHA 2025

We've had a wonderful first day at #EHA2025! Thank you to Amer Zeidan of @yalecancer.bsky.social, who shared interesting insights into the use of immune checkpoint inhibition in MDS, the KOMET-017 trial, & more!

Stay tuned 👉VJHemOnc.com!

#MDSsm #HemOnc #LeuSM #AMLsm #BloodSky #CTSM #TrialUpdate

A real-world analysis found luspatercept more effective than ESAs for anemia treatment in patients with lower-risk MDS, according to research presented at #ASCO25. #MDSsm shorturl.at/IXHJo

#ASCO25 #mdssm Daver: Bexmarilimab in HR-MDS has excellent safety profile (13% dc for TEAE, IrAEs in 4%). ORR 72% in 1L, 63% in relapse. Encouraging responses in TP53m setting as well.

#ASCO25 #mdssm Daver: Macrophage checkpoint Clever-1 inhibition with Bexmarilimab (w Aza) in HR-MDS. Clever-1 involved in conversion of macrophage to pro-inflammatory phenotype.

#ASCO25 #mdssm Garcia-Manero: transfusion independence 76% with Luspa vs 56% with epo with median DOR and 150 vs 95wks. Median OS not NR with Luspa yet vs 46mo with Epo.